‌

US Patent 8168216 Treatment of triple receptor negative breast cancer

Patent 8168216 was granted and assigned to MediGene on May, 2012 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors

Is a

Patent

Patent attributes

Current Assignee

MediGene

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

81682160

Patent Inventor Names

Axel Mescheder0

Kay-Oliver Kliche0

Martine Piccart0

Date of Patent

May 1, 2012

Patent Application Number

122930390

Date Filed

March 16, 2007

Patent Primary Examiner

‌

Gollamudi Kishore

Patent abstract

The present invention relates to the use of a liposomal preparation for the manufacture of a pharmaceutical composition and the use of such a composition for the treatment of ‘triple receptor negative’ breast cancer.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 8168216 Treatment of triple receptor negative breast cancer

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API